Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

5786 - Monocyte-to-lymphocyte ratio in metastatic colorectal cancer: prognostic role evaluation and cut-off definition

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Translational Research

Tumour Site

Colon and Rectal Cancer

Presenters

Debora Basile

Citation

Annals of Oncology (2018) 29 (suppl_8): viii150-viii204. 10.1093/annonc/mdy281

Authors

D. Basile1, S.K. Garattini1, G. Pelizzari1, F. Cortiula2, L. Gerratana1, M. Cattaneo3, C. Corvaja1, A. Parnofiello3, V.J. Andreotti1, E. Bertoli1, C. Lisanti1, D. Iacono4, M. Casagrande4, G.G. Cardellino4, G. Miolo5, N. Pella4, G. Aprile6, A. Buonadonna5, G. Fasola4, F. Puglisi7

Author affiliations

  • 1 Department Of Medicine (dame), University of Udine, 33100 - Udine/IT
  • 2 Department Of Medicine (dame), University of Udine, Udine/IT
  • 3 Department Of Medicine (dame), University of Udine, 33100 - udine/IT
  • 4 Oncology, ASUIUD Azienda Ospedaliero-Universitaria di Udine, 33100 - udine/IT
  • 5 Department Of Medical Oncology And Cancer Prevention, CRO National Cancer Institute, 33081 - Aviano/IT
  • 6 Medical Oncology, ULSS 8 Berica - Vicenza, 36100 - Vicenza/IT
  • 7 University Of Udine - Udine, Italy; Department Of Medical Oncology And Cancer Prevention, CRO National Cancer Institute, 33081 - Aviano/IT

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 5786

Background

Changes in peripheral blood cells composition may reflect tumor immune microenvironment and its role in cancer growth control. High monocyte-to-lymphocyte ratio (MLR) could be a sign of tumor’s recruitment of suppressive cells, showing a prognostic role in many cancer types. This study aimed to evaluate the prognostic role of MLR in metastatic colorectal cancer (MCRC).

Methods

This retrospective study analyzed a consecutive cohort of 392 patients (pts) with MCRC treated in 2004-2017 at the Oncology Departments of Aviano and Udine (Italy). The prognostic impact of MLR on overall survival (OS) was evaluated with uni and multivariate Cox regression analyses. The best cut-off value to predict survival was defined through ROC analysis.

Results

Before first line therapy, 269 pts (69%) were aged <70, 120 pts (31%) had a right tumor, 150 pts (38%) a left tumor and 117 pts (30%) a rectal one. Of note, 105 pts (27%) received metastasectomy and 142 pts had >1 metastasis. Metastasis were more frequent in liver (40%), lung (20%) and peritoneum (20%) Overall, 57% had a KRAS mutation (m) and 11% had a BRAFm. At median follow-up of 60 months, median OS was 26 months. At univariate analysis, older age (HR 1.61, p < 0.001), nodes (pN2 HR 1.48, p = 0.036; pN3 HR 2.52, p = 0.001), KRASm (HR 1.36, p = 0.020) and MLR (HR 3.32, p < 0.001) were associated with worse OS. Conversely, sidedness (left HR 0.65, p = 0.003; rectum HR 0.73, p = 0.042), metastasectomy (HR 0.36, p < 0.001) and adjuvant chemotherapy (HR 0.66, p = 0.008) were associated with better OS. By multivariate analysis, sidedness and metastasectomy confirmed a better OS, while MLR (HR 3.20, p < 0.001), nodes (pN2 HR 1.89, p = 0.006; pN3 HR 2.25, p = 0.014), and KRASm (HR 1.50, p < 0.001) were associated with worse OS. The adoption of the cut-off value for MLR (i.e. 0.44) predicted worse OS both in univariate (HR 2.23, p < 0.001) and multivariate (HR 2.41; p < 0.001) analyses. Moreover, MLR was associated with number of metastatic sites (p < 0.001), type of sites (p < 0.001), sidedness (p = 0.001) and LDH level (p < 0.001).

Conclusions

High MLR is an independent prognostic factor associated with worse OS and pathological features of MCRC. Further studies are needed to confirm these data.

Clinical trial identification

Legal entity responsible for the study

University of Udine.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.